Agenus Inc (NASDAQ: AGEN) is pleased to announce the U.S. Food and Drug Administration (FDA)’s stand concerning its License Application. The company sent an application to the body to review Biologics License Application (BLA) for balstilimab. Company’s efforts to treat severe conditions The company developed the anti-PD-1 antibody to aid in […]